MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED (MVP)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MVP

MVP - MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 1.38
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.70

20 Oct
2025

-0.015

OPEN

$0.73

-2.10%

HIGH

$0.75

28,164

LOW

$0.70

TARGET
$0.85 21.4% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
MVP: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 0.1 - 1.8 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 05/03 - ex-div 2c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx0.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx39.1 M
Book Value Per Share xxxxxxxxxxxxxxx48.9
Net Operating Cash Flow xxxxxxxxxxxxxxx0.0 M
Net Profit Margin xxxxxxxxxxxxxxx0.24 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx0.19 %
Return on Invested Capital xxxxxxxxxxxxxxx0.18 %
Return on Assets xxxxxxxxxxxxxxx0.14 %
Return on Equity xxxxxxxxxxxxxxx0.19 %
Return on Total Capital xxxxxxxxxxxxxxx-3.35 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-0.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx9 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx18 M
Price To Book Value xxxxxxxxxxxxxxx1.12

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx1.0 M
Capex % of Sales xxxxxxxxxxxxxxx2.66 %
Cost of Goods Sold xxxxxxxxxxxxxxx28 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx13 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

13/10/2025

1

Speculative Buy

$0.85

21.43%

Medical Developments International announced 1Q26 trading update with revenue lifting around 2.1% to $10.9m, which met Bell Potter's expectations.

The growth was generated from the Penthrox business, with the Respiratory business noted as seasonally weak over the period.

Management confirmed FY26 guidance for underlying earnings (EBIT), and cash on hand stood at around $16.1m. Positively, the analyst point to an improvement in operating cash flow of circa -$0.8m versus around -$2.7m in the previous period.

Demand for Penthrox from hospitals in Australia rose 26% on the previous year, with European in-market demand up around 12%.

No change to Speculative Buy rating. Target rises to 85c from 80c due to a lower cost of capital post the RBA interest rate cuts.

Bell Potter retains its EPS forecasts.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.80 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -0.50 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

MVP STOCK CHART

FNArena News on MVP

1
Rudi’s View: A Glass Half-Full Outlook

Sep 03 2025 - Rudi's View
2
FNArena Corporate Results Monitor – 22-08-2025

Aug 22 2025 - Australia
3
Weekly Ratings, Targets, Forecast Changes – 02-05-25

May 05 2025 - Weekly Reports
4
Weekly Ratings, Targets, Forecast Changes – 28-03-25

Mar 31 2025 - Weekly Reports
5
FNArena Corporate Results Monitor – 01-09-2023

Sep 01 2023 - Australia

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
2
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
3
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps
4
Earnings Result Leaves CSL Bloodied

Aug 21 2025 - Australia
5
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
6
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest
7
The Enigma Surrounding Clinuvel

Jul 03 2025 - Small Caps
8
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
9
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
10
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps